Linagliptin

IUPAC name:

8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione

CAS No.

668270-12-0

Molecular Weight:

472.5 g.mol−1

Molecular Formula:

C25H28N8O2

Granule:

Mechanism Of Action:

Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP). GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose.

Indication:

Linagliptin is used as monotherapy, or in combination with other antidiabetic medicines including insulin, for treatment of type 2 diabetes.

information

Category: Anti-Diabetic

January 21, 2024

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1

DABRAFENIB MESYLATE

Oncology

Cas No: 1195768-06-9

Mechanism Of Action: Dabrafenib is recognized as a competitive and highly selective inhibitor of BRAF. Its mechanism of action involves binding to the ATP pocket

Abemaciclib

Oncology

Cas No: 1231929-97-7

Mechanism Of Action: Abemaciclib demonstrates high selectivity in inhibiting CDK4 and CDK6 with potent activity in the low nanomolar range. By inhibiting the phosphorylation of

Sacubitril-Valsartan

Cardiovascular

Cas No: 936623-90-4

Mechanism Of Action: Sacubitril/valsartan is a medication that exerts its effects through the dual inhibition of neprilysin, an enzyme responsible for degrading certain peptides, and

Roxadustat

Anti-Anemic

Cas No: 808118-40-3

Mechanism Of Action: Anemia is a common complication of chronic kidney disease that can be caused by reduced production of renal erythropoietin (EPO), functional iron